Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

British Medical Journal

Volumn 332, Issue 7553, 2006, Pages 1302-1305

  Kearney, Patricia M ^a   Baigent, Colin ^a   Godwin, Jon ^a   Halls, Heather ^a   Emberson, Jonathan R ^a   Patrono, Carlo ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; VALDECOXIB;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENZYME INHIBITION; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; INCIDENCE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; ATHEROSCLEROSIS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATHEROSCLEROSIS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS;

EID: 33744976771     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.332.7553.1302     Document Type: Article

References (6)

1. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cydooxygenase-2. N Engl J Med 2001;345:433-42.
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
3. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
4. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
5. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
6. Baigent C, Patrono C. Selective cydooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum 2003;48:12-20.